Published in J Exp Med on June 09, 2014
Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma | NCT01111188
Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells. Cell (2016) 2.10
Man's best friend: what can pet dogs teach us about non-Hodgkin's lymphoma? Immunol Rev (2015) 0.85
Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1. Leukemia (2015) 0.82
Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma. Clin Cancer Res (2016) 0.75
Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors. Nat Cell Biol (2017) 0.75
Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol (2000) 128.08
An integrated map of genetic variation from 1,092 human genomes. Nature (2012) 59.82
A census of human cancer genes. Nat Rev Cancer (2004) 36.20
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics (2004) 24.18
An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature (2005) 22.40
Cancer cell cycles. Science (1996) 21.29
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet (2010) 10.97
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature (2011) 9.71
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol (2011) 9.60
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature (2004) 8.76
Mutual exclusivity analysis identifies oncogenic network modules. Genome Res (2011) 7.22
Follicular lymphoma international prognostic index. Blood (2004) 7.20
Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell (1992) 6.08
Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet (2011) 6.06
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A (2008) 5.90
Cyclin D as a therapeutic target in cancer. Nat Rev Cancer (2011) 5.76
Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther (2004) 5.69
BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. Nat Immunol (2005) 3.75
Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol (2006) 3.63
The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell (2011) 2.83
The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J (1996) 2.71
Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res (2010) 2.41
VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia. Blood (2003) 2.05
Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res (2011) 2.03
Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet (2013) 1.93
Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood (2013) 1.86
Genetics of follicular lymphoma transformation. Cell Rep (2014) 1.70
Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival. Oncogene (1996) 1.51
Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. J Exp Med (2011) 1.45
p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood (1998) 1.45
Bcl-2 retards cell cycle entry through p27(Kip1), pRB relative p130, and altered E2F regulation. Mol Cell Biol (2000) 1.35
A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood (2002) 1.32
Prognostic factors in follicular lymphoma. J Clin Oncol (2010) 1.31
A closer look at follicular lymphoma. N Engl J Med (2007) 1.20
EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood (2013) 1.17
cAMP-induced degradation of cyclin D3 through association with GSK-3beta. J Cell Sci (2004) 1.10
Grading of follicular lymphoma: comparison of routine histology with immunohistochemistry. Arch Pathol Lab Med (2007) 1.06
Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood (1998) 1.06
Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood (1995) 0.97
Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. Blood (2013) 0.96
Prognostic significance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma. Med Oncol (2001) 0.92
A clinicopathologic evaluation of follicular lymphoma grade 3A versus grade 3B reveals no survival differences. Arch Pathol Lab Med (2004) 0.87
Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma. Leukemia (2000) 0.83